Effects of Empagliflozin Treatment on Glycerol-Derived Hepatic Gluconeogenesis in Adults with Obesity: A Randomized Clinical Trial.

ABSTRACT:

Objective

The aim of this study was to determine the effects of empagliflozin on glycerol-derived hepatic gluconeogenesis in adults with obesity without type 2 diabetes mellitus (T2DM) using oral carbon 13 (¹³ C)-labeled glycerol.

Methods

A randomized, double-blind, placebo-controlled trial was performed in participants with magnetic resonance imaging assessment of body fat and measurement of glycerol-derived ¹³ C enrichment in plasma glucose by nuclear magnetic resonance spectroscopy following ingestion of [U-¹³ C₃ ]glycerol. Participants were randomized to oral empagliflozin 10 mg once daily or placebo for 3 months. Glycerol-derived ¹³ C enrichment studies were repeated, and treatment differences in the mean percentage

SUBMITTER: Neeland IJ 

PROVIDER: S-EPMC7316140 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature